ANAPTYSBIO, INC. Debt Securities, Available-for-sale
ANAPTYSBIO, INC. (ANAB) had Debt Securities, Available-for-sale of $80.06 million as of 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2026-09-21
- 2026-06-30: Debt Securities, Available-for-sale $80.06M.
- 2026-03-31: Debt Securities, Available-for-sale $37.99M.
- 2025-12-31: Debt Securities, Available-for-sale $73.44M.
- 2025-09-30: Debt Securities, Available-for-sale $146.82M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2026-06-30 | $80.06M 10-KT · filed 2026-09-21 |
| 2026-03-31 | $37.99M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $73.44M 10-KT · filed 2026-09-21 |
| 2025-09-30 | $146.82M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $249.41M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $289.30M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $302.73M 10-K · filed 2026-03-03 |
| 2024-09-30 | $266.45M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $321.63M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $316.44M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $381.96M 10-K · filed 2025-02-27 |
| 2023-09-30 | $426.95M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $453.52M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $431.52M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $512.87M 10-K · filed 2024-03-11 |
| 2022-09-30 | $531.93M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $503.93M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $430.40M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $119.47M 10-K · filed 2023-03-01 |
| 2021-09-30 | $52.98M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $64.08M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $103.27M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $160.74M 10-K · filed 2022-03-07 |
| 2020-09-30 | $165.37M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $171.03M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $247.38M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $257.51M 10-K · filed 2021-02-25 |
| 2019-09-30 | $261.52M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $326.42M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $386.52M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $404.31M 10-K · filed 2019-02-28 |
| 2018-09-30 | $221.34M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $246.07M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $242.57M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $251.00M 10-K · filed 2018-03-05 |
| 2017-09-30 | $90.05M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $89.52M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $28.68M 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |